Among patients receiving anti-EGFR-based therapies, 23 (34%) had a RAS and BRAF wild-type tumour, while a RAS or BRAF mutation was found in 16 (23%) and 6 (9%) cases, respectively. The gene discussed is EGFR; the disease is neoplasm.